Methylene blue and Rizatriptan interaction

Methylene blue and Rizatriptan: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Methylene blue (PROVAYBLUE) label · effective 2025-05-28

Major

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids.

Boxed warningby drug classView label on DailyMed
Major

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS See full prescribing information for complete boxed warning.

Boxed warningby drug classView label on DailyMed
Major

PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids.

Boxed warningby drug classView label on DailyMed
Major

Serotonin Syndrome with Concomitant Use of Serotonergic Drugs and Opioids The development of serotonin syndrome has been reported with the use of methylene blue class products.

Warnings and precautionsby drug classView label on DailyMed
Major

Avoid concomitant use of PROVAYBLUE with serotonergic drugs and opioids.

Warnings and precautionsby drug classView label on DailyMed

From the Rizatriptan (MAXALT) label · effective 2026-01-29

Major

Monoamine Oxidase Inhibitors MAXALT is contraindicated in patients taking MAO-A inhibitors and non-selective MAO inhibitors.

Drug interactionsby drug classView label on DailyMed
Moderate

Plasma concentrations of rizatriptan may be increased by drugs that are selective MAO-A inhibitors (e.g., moclobemide) or nonselective MAO inhibitors [type A and B] (e.g., isocarboxazid, phenelzine, tranylcypromine, and pargyline).

Drug interactionsby drug classView label on DailyMed
Minor

Serotonin Syndrome Serotonin syndrome may occur with triptans, including MAXALT particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions (7.5) ] .

Warnings and precautionsby drug classView label on DailyMed
Minor

Drug Interactions [See also Drug Interactions (7) .] Monoamine oxidase inhibitors : Rizatriptan is principally metabolized via monoamine oxidase, 'A' subtype (MAO-A).

Drug interactionsby drug classView label on DailyMed
Minor

The interaction would be expected to be greater with irreversible MAO inhibitors.

Drug interactionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.